PPIPT02465
Target Protein Information
| Protein_Name | Kallikrein-4 |
|---|---|
| Protein_Sequence | MATAGNPWGWFLGYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAALVMENELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEASLSVRHPEYNRPLLANDLMLIKLDESVSESDTIRSISIASQCPTAGNSCLVSGWGLLANGRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGGGHDQKDSCNGDSGGPLICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEKTVQAS |
| Organism_Source | Homo sapiens |
| Functional_Classification | Serine endopeptidase (kallikrein family) |
| Cellular_Localization | Extracellular |
| Gene_Names | KLK4 |
| UniProt_ID | Q9Y5K2 |
| Protein-Protein Interaction Networks | |
Peptide Basic Information
| Peptide_Name | peptide GYLQGLVSF |
|---|---|
| Peptide_Sequence | GYLQGLVSF |
| Peptide_Length | 9 |
| Peptide_SMILES | CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C |
| Chemical_Modification | None |
| Cyclization_Method | none |
| Linear/Cyclic | Linear |
| N-terminal_Modification | free |
| C-terminal_Modification | free |
| Amino_Acid_Distribution | |
|
|
|
Peptide Physicochemical
| Molecular_Weight | 983.13 |
|---|---|
| Aliphatic_Index | 118.88889 |
| Aromaticity | 0.22222 |
| Average_Rotatable_Bonds | 3.33333 |
| Charge_at_pH_7 | -0.00287 |
| Isoelectric_point | 6.09320 |
|---|---|
| Number_of_Hydrogen_Bond_Acceptors | 13 |
| Number_of_Hydrogen_Bond_Donors | 13 |
| Topological_Polar_Surface_Area | 379.67000 |
| X_logP_energy | -2.26350 |
Interaction Information
| Affinity | KD=0.86 uM |
|---|---|
| Affinity_Assay | Surface Plasmon Resonance |
| PDB_ID | None |
| Type | Affinity ligand |
| Structure | |
Reference Information
| Document_Type | Patent |
|---|---|
| Title | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS |
| Release_Year | 2022 |
| Patent_ID | US20220143162A1 |